REG - Roquefort Theraptcs. - Non-Executive Director Appointment

Roquefort TherapeuticsAnnouncement

20/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220420:nRST6627Ia&default-theme=true

RNS Number : 6627I  Roquefort Therapeutics PLC  20 April 2022

20 April 2022

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Non-Executive Director Appointment

Significant Clinical Trial Expertise

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company
focused on early-stage opportunities in the biotechnology sector, is pleased
to announce the appointment of Dr Simon Sinclair as a Non-Executive Director
with immediate effect.  Dr Sinclair is a commercial physician scientist
leader with 20 years' pharma, medtech and consumer healthcare industry
experience in translational medicine, clinical development, medical affairs,
evidence-based market access, medical safety, vigilance and real-world
evidence in both executive and non-executive roles.

 

During his career, Dr Sinclair has held senior roles at Johnson and Johnson
and Merck & Co.  At Johnson and Johnson, Dr Sinclair held the role of VP
Medical Affairs (CMO) EMEA where he created an integrated Medical Affairs
function for Johnson and Johnson Medical Devices across EMEA, a $6bn segment
of the business.  Prior to that he served as International Clinical Director
and WW VP Medical Affairs where he set up and led the Medical Affairs function
globally for DePuy Synthes (part of Johnson and Johnson) Joint Reconstruction.
He was also responsible for DePuy Orthopaedics' non-US Clinical research
strategy and execution. He guided new product development, registration and
post-market strategies from a Clinical Evidence perspective. He also oversaw
the company's global Medical Safety product surveillance.

 

At Merck & Co, Dr Sinclair was Head of Global Trial Optimization, where he
revolutionised Merck's approach to the conduct of its clinical trials
globally.  He developed and installed a new strategy and process to oversee
the execution of clinical development programmes from proof of concept
onwards. This included ensuring the design of clinical studies was optimised
for execution; the definition of geographical and temporal models for clinical
programs and individual studies; the development and implementation of
impactful patient recruitment and retention strategies; and risk assessment,
mitigation and control during study conduct.  Dr Sinclair also served as
Senior Director Clinical Research Operations, USA at Merck, where he led
clinical research operations in several therapeutic areas, including
neuroscience, ophthalmology, respiratory, gastro-intestinal, endocrinology,
clinical pharmacology and experimental medicine.

 

Dr Sinclair is currently Chief Safety Officer of Reckitt Benckiser Group plc
("Reckitt") where he is responsible for guiding and evaluating the safety of
all its products to protect its consumers, and for building and maintaining
consumers' trust in Reckitt. Simon also holds the role of Executive Director
and Chair at the Reckitt Global Hygeine Institute, where using a $25m seed
fund from Reckitt, he created and established the new non-profit
organisation.   Additionally, Dr Sinclair is a Non-Executive Board member of
Ondine Biomedical Inc., an AIM listed life sciences company focused on
photodisinfection-based therapies to prevent and treat a broad spectrum of
infections, including those caused by drug-resistant pathogens.  He is also
Non-Executive Director at Renovos Biologics Limited, an orthopaedic biotech
company.

 

Dr Sinclair is a renowned scientist with a PhD in neural transplantation from
Cambridge University, medical degree and numerous publications in scientific
journals throughout his career.

 

 

Stephen West, Roquefort Therapeutics Executive Chairman, commented:

"We are delighted to welcome Simon Sinclair to the Board of Roquefort
Therapeutics, where his directly relevant expertise in driving clinical
programmes will be of signficiant value to the Company. Simon has extensive
experience in briging novel, safe and meaningful technologies and therapies to
global healthcare systems and patients worldwide and I look forward to working
him to drive our pre-clinical programmes forward to clinical trials and
beyond."

 

Commenting on his appointment, Roquefort Therapeutics NED Simon Sinclair said:

"I am excited to join the Board of Roquefort Therapeutics. The science behind
the Company's studies and therapeutic potential of Midkine really stood out to
me and underpinned my decision to join the Board.  I look forward to working
with the team on developing its preclinical drug programme in cancer and
exploring further health benefits that inhibiting Midkine could potentially
bring to patients."

 

-Ends-

 

 
Enquiries:
 Roquefort Therapeutics plc
 Stephen West (Chairman)                    +44 (0)20 3290 9339

 Buchanan (Public Relations)

 Ben Romney / Jamie Hooper / George Beale   +44 (0)20 7466 5000

 Optiva Securities Limited (Broker)
 Christian Dennis                           +44 (0)20 3411 1881

 

For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com (http://www.roquefortplc.com)  and @RoquefortTherap on
Twitter.

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company
developing products through the pre-clinical phase prior to partnering or
selling to big pharma.  The Company is focused on developing first in class
Midkine inhibiting RNA therapeutics drugs for the treatment of cancer, chronic
inflammation, autoimmune disorder and COVID-19.  Recent progress within mRNA
therapeutics has led to a reduction in drug development timelines and costs,
increasing the chance of early value creation.

 

Through extensive research resulting in validation through publication in over
1,000 scientific publications, Roquefort Therapeutics has identified the
potential to exploit the broad therapeutic potential of Midkine for a number
of clinical indications of significant unmet need. Roquefort Therapeutics
holds the largest global IP portfolio on Midkine. The Midkine blocking drug
development markets have significant global market potential (in the
multi-billion dollars). Roquefort Therapeutics's pre-clinical programme is
currently underway with an initial focus on cancer treatment aiming to improve
immunotherapy responses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLFIDSLIALIF